MarketCap
Fulcrum Therapeutics FULC
€ 3.27
-0.14%
Facebook
X
Telegram
Fulcrum Therapeutics Betriebsaufwand | FULC
Betriebsaufwand Jährlich Fulcrum Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 84.8 M | 102 M | 113 M | 119 M | 100 M | 80.4 M | 84.2 M | - | - | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 119 M | 80.4 M | 97.7 M |
Betriebsaufwand Vierteljährlich Fulcrum Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.3 M | 22.2 M | - | 21.9 M | 19.8 M | 20.4 M | - | 25.1 M | 27.5 M | 29.8 M | - | 28.2 M | 28.2 M | 28.2 M | - | 25.5 M | 36.1 M | 28.6 M | - | 25.7 M | 24.1 M | 21.8 M | - | 21 M | 17.9 M | 19.5 M | - | 17 M | 13.5 M | 37.2 M | - | 9.09 M | 7.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 37.2 M | 7.85 M | 23.4 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Auris Medical Holding Ltd.
EARS
|
7.26 M | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
278 M | - | 0.34 % | $ 2.98 B |  USA |
 |
ERYTECH Pharma S.A.
ERYP
|
33.8 M | - | 1.3 % | $ 27.7 M |  France |
 |
GW Pharmaceuticals plc
GWPH
|
541 M | - | - | $ 6.81 B |  Britain |
 |
Kadmon Holdings, Inc.
KDMN
|
109 M | - | - | $ 1.7 B | USA |
 |
Liminal BioSciences
LMNL
|
95.4 M | - | - | $ 256 M |  Canada |
 |
Neos Therapeutics, Inc.
NEOS
|
49.9 M | - | -2.54 % | $ 57.2 M | USA |
 |
Odonate Therapeutics, Inc.
ODT
|
127 M | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
336 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
102 M | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
46.7 M | - | - | $ 1.77 B | USA |
 |
Translate Bio, Inc.
TBIO
|
146 M | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
61.6 M | - | - | $ 1.94 B | Canada |
 |
Urovant Sciences Ltd.
UROV
|
139 M | - | - | $ 532 M | Britain |
 |
Acceleron Pharma Inc.
XLRN
|
210 M | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
1.09 B | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
242 M | - | -4.97 % | $ 664 M | USA |
 |
Yunhong International
ZGYH
|
309 K | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
80.4 M | - | -7.58 % | $ 264 M | USA |
 |
Leap Therapeutics
LPTX
|
41.1 M | - | 368.57 % | $ 41.9 M | USA |
 |
Cortexyme
CRTX
|
58.1 M | - | -1.05 % | $ 67.1 M | USA |
 |
Aptorum Group Limited
APM
|
31 K | - | - | $ 5.72 M | China |
 |
FSD Pharma
HUGE
|
15.3 M | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
61.3 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
206 M | - | - | $ 3.85 B | USA |
 |
ARCA biopharma
ABIO
|
122 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
19.6 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
948 M | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
84 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bio-Path Holdings
BPTH
|
12 M | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
26.7 M | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
66.9 M | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
18.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
9.17 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
9.17 M | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
32.3 M | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
3.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
8.75 M | - | - | $ 40.5 M | USA |